Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSTU:X2S +1.58%72 Net Current Asset Value is €1.57 as of Dec. 2025, which is 100% below its 10-year median of 3.19. GuruFocus rates STU:X2S with a GF Score™ of 72/100 and a GF Value™ of €2.33 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 75 Medical Distribution companies, Sinopharm Group Co ranks better than 80% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Sinopharm Group Co's net current asset value per share for the quarter that ended in Dec. 2025 was €1.57.
The historical rank and industry rank for Sinopharm Group Co's Net Current Asset Value or its related term are showing as below:
STU:X2S'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.23 Med: 3.19 Max: 11.49
Current: 1.23
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Sinopharm Group Co was 11.49. The lowest was 1.23. And the median was 3.19.
STU:X2S's Price-to-Net-Current-Asset-Value is ranked better than 80% of 75
companies
in the Medical Distribution industry
Industry Median: 3.22
vs STU:X2S: 1.23
Sinopharm Group Co (STU:X2S) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Sinopharm Group Co Net Current Asset Value Related Terms
Sinopharm Group Co Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:X2S vs MCK, CAH, COR: Net Current Asset Value Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Price-to-Net-Current-Asset-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €1.57 mean?
Sinopharm Group Co (STU:X2S) has a Net Current Asset Value of €1.57 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Sinopharm Group Co and its competitors. This is 51% below median its historical median of 3.19. Over the past decade, Sinopharm Group Co's Net Current Asset Value has ranged from 1.23 to 11.49. According to the industry distribution chart, Sinopharm Group Co ranks #15 out of 75 companies in the Medical Distribution industry, placing it in the top 20%.
Is Sinopharm Group Co's Net Current Asset Value too high?
Sinopharm Group Co's current Net Current Asset Value of €1.57 is 51% below median its 10-year median of 3.19. Over the past 10 years, this metric has ranged from a low of 1.23 to a high of 11.49. Based on the distribution chart, Sinopharm Group Co ranks #15 out of 75 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Net Current Asset Value compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #15 out of 75 companies for Net Current Asset Value. This places Sinopharm Group Co in the top 20% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 3.22. Historically, Sinopharm Group Co's own Net Current Asset Value has ranged from 1.23 to 11.49 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Distribution company?
The median Net Current Asset Value among Medical Distribution companies is 3.22, based on 75 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Net Current Asset Value is 3.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Net Current Asset Value is €1.57, which is 51% below median its own 10-year median of 3.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (STU:X2S) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.33, compared to a current price of €1.96 — trading 16% below its estimated fair value. The current Net Current Asset Value is €1.57, which is 51% below median its 10-year median of 3.19. Sinopharm Group Co's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Sinopharm Group Co (STU:X2S), the current Net Current Asset Value is €1.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (STU:X2S) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of €1.96 is trading 16% below its estimated GF Value™ of €2.33.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for STU:X2S:
Net Current Asset Value: €1.57 (51% below median its 10-year median of 3.19)
GF Value™: €2.33 vs. price of €1.96 (16% below fair value)
No single metric tells the full story. See the STU:X2S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
72GF Score
Get the complete analysis for STU:X2S
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:X2S has been successfully added to your 
